Personalized treatment approaches in intraocular cancer

Yating Liu; Alexander C. Rokohl; Yongwei Guo; Ke Yao; Wanlin Fan; Ludwig M. Heindl

doi:10.1016/j.aopr.2024.03.005

您当前的位置：

首页 >

文章列表页 >

Personalized treatment approaches in intraocular cancer

Review | 更新时间：2024-12-14

- Personalized treatment approaches in intraocular cancer
- AOPR Vol. 4, Issue 3, Pages: 112-119(2024)
- 作者机构：
  
  1. Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne,Cologne,Germany
  2. Center for Integrated Oncology (CIO), Aachen-Bonn-Cologne-Duesseldorf,Cologne,Germany
  3. Eye Center, The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,China
- 作者简介：
- 基金信息：
- DOI：10.1016/j.aopr.2024.03.005
  CLC：
- Published：2024，
- 稿件说明：
移动端阅览
YATING LIU, ALEXANDER C. ROKOHL, YONGWEI GUO, et al. Personalized treatment approaches in intraocular cancer. [J]. Aopr, 2024, 4(3): 112-119.
DOI：

YATING LIU, ALEXANDER C. ROKOHL, YONGWEI GUO, et al. Personalized treatment approaches in intraocular cancer. [J]. Aopr, 2024, 4(3): 112-119. DOI： 10.1016/j.aopr.2024.03.005.

摘要

Abstract

BackgroundIntraocular malignant tumors represent a severe disease that threatens vision as well as life. To better extend the life of the patient

preserve visual function

and maintain ocular aesthetics

selecting the appropriate timing and methods of treatment becomes crucial.Main textWith the continuous advancement of medical technology

the techniques and methods for treating intraocular malignant tumors are constantly evolving. While surgery was once considered the optimal method to prolong patient survival and prevent local recurrence

the discovery and application of various treatments such as radiotherapy

laser therapy

chemotherapy

cryotherapy

and monoclonal antibodies have led to a greater diversity of treatment options. This diversity offers more possibilities to develop personalized treatment plans

and thereby maximize patient benefit. This article reviews the various treatment methods for intraocular malignant tumors

including indications for treatment

outcomes

and potential complications.ConclusionsDifferentiating small intraocular malignant tumors from pigmented lesions is challenging

and ongoing monitoring with regular follow-up is required. Small to medium-sized tumors can be treated with radiotherapy combined with transpupillary thermotherapy. Depending on the tumor's distance from the optic disc

surgery with partial resection may be considered for distant tumors

while proximal tumors may require complete enucleation. Systemic chemotherapy has been widely applied to patients with retinal tumors

lymphomas

and intraocular metastatic cancers

but has limited efficacy in patients with choroidal melanoma. Antagonists of Vascular Endothelial Growth Factor (Anti-VEGF) drugs can improve patient vision and quality of life

while the efficacy of immunotherapy and molecular targeted therapy is still under research.

关键词

Keywords

Intraocular cancerUveal melanomaRetinoblastomaTreatment

references

1 T. KiveläThe epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death Br J Ophthalmol, 93 (9) (2009), pp. 1129-1131, 10.1136/bjo.2008.150292

2 H. Bai, J.J. Bosch, L.M. HeindlCurrent management of uveal melanoma: a review Clin Exp Ophthalmol, 51 (5) (2023), pp. 484-494, 10.1111/ceo.14214

3 Y. Guo, C. Shao, T. Blau, et al.Ocular metastasis of bronchial typical carcinoid J Thorac Oncol, 13 (9) (2018), pp. 1422-1423, 10.1016/j.jtho.2018.04.001

4 P. Jardel, W. Sauerwein, T. Olivier, et al.Management of choroidal metastases Cancer Treat Rev, 40 (10) (2014), pp. 1119-1128, 10.1016/j.ctrv.2014.09.006

5 L. Konstantinidis, B. DamatoIntraocular metastases--A review Asia Pac J Ophthalmol (Phila)., 6 (2) (2017), pp. 208-214, 10.22608/APO.201712

6 H. Dimaras, K. Kimani, E.A.O. Dimba, et al. Retinoblastoma. Lancet, 379 (9824) (2012), pp. 1436-1446, 10.1016/S0140-6736(11)61137-9

7 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries Lancet Global Health, 10 (8) (2022), pp. e1128-e1140, 10.1016/S2214-109X(22)00250-9

8 S. Kaliki, C.L. ShieldsUveal melanoma: relatively rare but deadly cancer Eye, 31 (2) (2017), pp. 241-257, 10.1038/eye.2016.275

9 M.S. Sagoo, H. Mehta, A.J. Swampillai, et al.Primary intraocular lymphoma Surv Ophthalmol, 59 (5) (2014), pp. 503-516, 10.1016/j.survophthal.2013.12.001

10 V. Kakkassery, S.E. Coupland, L.M. HeindlIris lymphoma-a systematic guide for diagnosis and treatment Surv Ophthalmol, 66 (1) (2021), pp. 41-53, 10.1016/j.survophthal.2020.06.003

11 M.J. Jager, C.L. Shields, C.M. Cebulla, et al.Uveal melanoma Nat Rev Dis Prim, 6 (1) (2020), p. 24, 10.1038/s41572-020-0158-0

12 G.P. Giuliari, D.M. Hinkle, C.S. FosterLocal treatment for lymphoid malignancies of the eye Anti Cancer Agents Med Chem, 9 (10) (2009), pp. 1123-1128, 10.2174/187152009789735071

13 J. Shankar, B.E. Damato, P. HiscottPalliative vitrectomy for intraocular metastasis from cutaneous melanoma Eye, 16 (5) (2002), pp. 660-662, 10.1038/sj.eye.6700160

14 C. Chattopadhyay, D.W. Kim, D.S. Gombos, et al.Uveal melanoma: from diagnosis to treatment and the science in between Cancer, 122 (15) (2016), pp. 2299-2312, 10.1002/cncr.29727

15 T.L. Spencer, P.M BrianRetinoblastoma: presentation, evaluation, and diagnosis A. Hind Manaa (Ed.), In: Retinoblastoma. Rijeka: IntechOpen, Ch. 3 (2019) https://doi.org/10.5772/intechopen.85744

16 A. Muniyandi, N.R. Jensen, N. Devanathan, et al.The potential of aqueous humor sampling in diagnosis, prognosis, and treatment of retinoblastoma Invest Ophthalmol Vis Sci, 65 (1) (2024), p. 18, 10.1167/iovs.65.1.18

17 G. Balaban, F. Gilbert, W. Nichols, et al.Abnormalities of chromosome #13 in retinoblastomas from individuals with normal constitutional karyotypes Cancer Genet Cytogenet, 6 (3) (1982), pp. 213-221, 10.1016/0165-4608(82)90058-9

18 H. JenkinsonRetinoblastoma: diagnosis and management--the UK perspective Arch Dis Child., 100 (11) (2015), pp. 1070-1075, 10.1136/archdischild-2014-306208

19 T. Kaburaki, K. TaokaDiagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives Jpn J Ophthalmol, 67 (4) (2023), pp. 363-381, 10.1007/s10384-023-00997-6

20 B. Sobolewska, S.-P. Chee, F. Zaguia, et al.Vitreoretinal lymphoma Cancers, 13 (16) (2021), 10.3390/cancers13163921

21 R.S. Huang, A. Mihalache, M.M. Popovic, et al.Diagnostic methods for primary vitreoretinal lymphoma: a systematic review Surv Ophthalmol, 69 (3) (2024 May-Jun), pp. 456-464, 10.1016/j.survophthal.2023.12.001

22 H. Takase, A. Arai, Y. Iwasaki, et al.Challenges in the diagnosis and management of vitreoretinal lymphoma - clinical and basic approaches Prog Retin Eye Res, 90 (2022), p. 101053, 10.1016/j.preteyeres.2022.101053

23 M.E. Aronow, C.A. Portell, J.W. Sweetenham, et al.Uveal lymphoma: clinical features, diagnostic studies, treatment selection, and outcomes Ophthalmology, 121 (1) (2014), pp. 334-341, 10.1016/j.ophtha.2013.09.004

24 Y. Di, J. Ye, R. Han, et al.Case report: ocular manifestations and treatments of ciliary body involvement by lymphoma Front Oncol, 11 (2021), p. 718759, 10.3389/fonc.2021.718759

25 C. Schiemenz, S. Lüken, A.M. Klassen, et al.[Clinical procedures for intraocular lymphomas] Ophthalmologie, 119 (7) (2022), pp. 675-685, 10.1007/s00347-022-01651-1

26 R. Parrozzani, L. Frizziero, I. Testi, et al.Intraocular metastases secondary to breast carcinoma correlates with upregulation of estrogen and progesterone receptor expression in the primary tumor Invest Ophthalmol Vis Sci, 57 (10) (2016), pp. 3944-3948, 10.1167/iovs.16-19695

27 V.S. Vempuluru, S. Jakati, R. Krishnamurthy, et al.Glaucoma as the presenting sign of intraocular tumors: beware of the masquerading sign Int Ophthalmol, 40 (7) (2020), pp. 1789-1795, 10.1007/s10792-020-01348-x

28 A. Jindal, G. Kapatia, G. GuptaOcular metastasis from renal malignancies - a comprehensive review Indian J Ophthalmol, 71 (10) (2023), pp. 3281-3289, 10.4103/IJO.IJO_3073_22

29 V.M. CohenOcular metastases Eye, 27 (2) (2013), pp. 137-141, 10.1038/eye.2012.252

30 D.C. Branisteanu, C.M. Bogdanici, D.E. Branisteanu, et al.Uveal melanoma diagnosis and current treatment options Exp Ther Med, 22 (6) (2021), p. 1428, 10.3892/etm.2021.10863

31 S. Natesh, K.J. Chin, P.T. FingerChoroidal metastases fundus autofluorescence imaging: correlation to clinical, OCT, and fluorescein angiographic findings Ophthalmic Surg Laser Imag, 41 (4) (2010), pp. 406-412, 10.3928/15428877-20100426-03

32 C.L. Shields, S. Kaliki, A. Hutchinson, et al.Iris nevus growth into melanoma: analysis of 1611 consecutive eyes: the ABCDEF guide Ophthalmology, 120 (4) (2013), pp. 766-772, 10.1016/j.ophtha.2012.09.042

33 C.L. Shields, J. Cater, J.A. Shields, et al.Combination of clinical factors predictive of growth of small choroidal melanocytic tumors Arch Ophthalmol, 118 (3) (2000), pp. 360-364, 10.1001/archopht.118.3.360

34 H.B. StallardSurgery of malignant melanoma of the iris Br J Ophthalmol, 35 (12) (1951), pp. 774-783, 10.1136/bjo.35.12.774

35 J.M. Mor, K.R. Koch, L.M. Heindl[Diagnosis and therapy of Iris lesions] Klin Monbl Augenheilkd, 234 (12) (2017), pp. 1541-1554, 10.1055/s-0043-120093

36 L.M. Heindl, K.R. Koch, M.M. Hermann, et al.Block excision of iridociliary tumors enables molecular profiling and immune vaccination Ophthalmology, 124 (2) (2017), pp. 268-270, 10.1016/j.ophtha.2016.09.011

37 J.M. Caminal, D. Lorenzo, C. Gutierrez, et al.Local resection in choroidal melanoma: a review J Clin Med, 11 (23) (2022), 10.3390/jcm11237156

38 J.A. Shields, C.L. Shields, P. Shah, et al.Partial lamellar sclerouvectomy for ciliary body and choroidal tumors Ophthalmology, 98 (6) (1991), pp. 971-983, 10.1016/s0161-6420(91)32194-8

39 B. Damato, A.G. JonesUveal melanoma: resection techniques Ophthalmol Clin North Am, 18 (1) (2005), 10.1016/j.ohc.2004.08.010

40 T. Kivelä, I. Puusaari, B. DamatoTransscleral resection versus iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study Ophthalmology, 110 (11) (2003), pp. 2235-2244, 10.1016/j.ophtha.2003.02.001

41 M. Dogrusöz, M.J. Jager, B. DamatoUveal melanoma treatment and prognostication Asia Pac J Ophthalmol (Phila), 6 (2) (2017), pp. 186-196, 10.22608/APO.201734

42 C.L. Shields, J.A. Shields, P. De Potter, et al.Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment Ophthalmology, 100 (2) (1993), pp. 216-224, 10.1016/s0161-6420(93)31667-2

43 C.L. Shields, Z. Bas, S. Tadepalli, et al.Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centre Br J Ophthalmol, 104 (11) (2020), pp. 1548-1555, 10.1136/bjophthalmol-2019-315572

44 A.E. MaumeneeAn evaluation of enucleation in the management of uveal melanomas Am J Ophthalmol, 87 (6) (1979), pp. 741-760, 10.1016/0002-9394(79)90369-6

45 T. Riley, D. HarshmanTreatment options for choroidal malignant melanoma: a case report featuring transpupillary thermotherapy Optometry, 75 (2) (2004), pp. 103-114, 10.1016/s1529-1839(04)70022-6

46 A.D. Singh, I.G. Rennie, T. Kivela, et al.The Zimmerman-McLean-Foster hypothesis: 25 years later Br J Ophthalmol, 88 (7) (2004), pp. 962-967, 10.1136/bjo.2003.029058

47 B.S. HawkinsThe Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24 Am J Ophthalmol, 138 (6) (2004), pp. 936-951, 10.1016/j.ajo.2004.07.006

48 E.S. Gragoudas, W. Li, A.M. Lane, et al.Risk factors for radiation maculopathy and papillopathy after intraocular irradiation Ophthalmology, 106 (8) (1999), 10.1016/S0161-6420(99)90455-4

49 T.D. Papakostas, A.M. Lane, M. Morrison, et al.Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas JAMA Ophthalmol, 135 (11) (2017), pp. 1191-1196, 10.1001/jamaophthalmol.2017.3805

50 D.G. Pradhan, A.L. Sandridge, P. Mullaney, et al.Radiation therapy for retinoblastoma: a retrospective review of 120 patients Int J Radiat Oncol Biol Phys, 39 (1) (1997), pp. 3-13, 10.1016/s0360-3016(97)00156-9

51 B.Y. Brewington, Y.F. Shao, F.H. Davidorf, et al.Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions Clin Ophthalmol, 12 (2018), pp. 925-934, 10.2147/OPTH.S129645

52 P.T. FingerRadiation therapy for choroidal melanoma Surv Ophthalmol, 42 (3) (1997), pp. 215-232, 10.1016/s0039-6257(97)00088-x

53 E.T. Detorakis, R.E. Engstrom, R. Wallace, et al.Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma Ophthalmology, 112 (3) (2005), pp. 505-510, 10.1016/j.ophtha.2004.09.028

54 K. Bilmin, K.J. Synoradzki, A.M. Czarnecka, et al.New perspectives for eye-sparing treatment strategies in primary uveal melanoma Cancers, 14 (1) (2021), 10.3390/cancers14010134

55 R.W. Milam, S.A. Batson, M.P. Breazzano, et al.Modern and novel radiotherapy approaches for the treatment of uveal melanoma Int Ophthalmol Clin, 57 (1) (2017), pp. 11-27, 10.1097/IIO.0000000000000153

56 T. Parker, G. Rigney, J. Kallos, et al.Gamma knife radiosurgery for uveal melanomas and metastases: a systematic review and meta-analysis Lancet Oncol, 21 (11) (2020), pp. 1526-1536, 10.1016/S1470-2045(20)30459-9

57 R. Woodburn, R. Danis, R. Timmerman, et al.Preliminary experience in the treatment of choroidal melanoma with gamma knife radiosurgery J Neurosurg, 93 (Suppl 3) (2000), pp. 177-179, 10.3171/jns.2000.93.supplement

58 C.L. Shields, J.A. Shields, N. Perez, et al.Primary transpupillary thermotherapy for small choroidal melanoma in 256 consecutive cases: outcomes and limitations Ophthalmology, 109 (2) (2002), pp. 225-234, 10.1016/s0161-6420(01)00902-2

59 C.L. Shields, M.C. Santos, W. Diniz, et al.Thermotherapy for retinoblastoma Arch Ophthalmol, 117 (7) (1999), pp. 885-893, 10.1001/archopht.117.7.885

60 C.L. Shields, S.E. Lally, A.M. Leahey, et al.Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy Curr Opin Ophthalmol, 25 (5) (2014), pp. 374-385, 10.1097/ICU.0000000000000091

61 J. WintherPhotodynamic therapy effect in an intraocular retinoblastoma-like tumour assessed by an in vivo to in vitro colony forming assay Br J Cancer, 59 (6) (1989), pp. 869-872, 10.1038/bjc.1989.184

62 I.D. Fabian, A.W. Stacey, V. Papastefanou, et al.Primary photodynamic therapy with verteporfin for small pigmented posterior pole choroidal melanoma Eye, 31 (4) (2017), pp. 519-528, 10.1038/eye.2017.22

63 S. Tuncer, Z. CebeciDramatic regression of presumed acquired retinal astrocytoma with photodynamic therapy. Middle East Afr J Ophthalmol, 21 (3) (2014), pp. 283-286, 10.4103/0974-9233.134699

64 S. Yordi, H. Soto, R.C. Bowen, et al.Photodynamic therapy for choroidal melanoma: what is the response rate? Surv Ophthalmol, 66 (4) (2021), pp. 552-559, 10.1016/j.survophthal.2020.09.006

65 M.A. Blasi, M. Laguardia, L. Tagliaferri, et al.Brachytherapy alone or with neoadjuvant photodynamic therapy for amelanotic choroidal melanoma: functional outcomes and local tumor control Retina, 36 (11) (2016), pp. 2205-2212, 10.1097/IAE.0000000000001048

66 D. Ancona-Lezama, L.A. Dalvin, C.L. ShieldsModern treatment of retinoblastoma: a 2020 review Indian J Ophthalmol, 68 (11) (2020), pp. 2356-2365, 10.4103/ijo.IJO_721_20

67 E.S. Rantala, M.M. Hernberg, S. Piperno-Neumann, et al.Metastatic uveal melanoma: the final frontier Prog Retin Eye Res, 90 (2022), p. 101041, 10.1016/j.preteyeres.2022.101041

68 C.-C. Chan, H.N. SenCurrent concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma Discov Med., 15 (81) (2013) PMID: 23449111 PMCID: PMC3745601

69 F.L. Munier, M. Beck-Popovic, G.L. Chantada, et al.Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity” Prog Retin Eye Res, 73 (2019), p. 100764, 10.1016/j.preteyeres.2019.05.005

70 D. Ancona-Lezama, L.A. Dalvin, J.A. Lucio-Alvarez, et al.Ophthalmic vascular events after intra-arterial chemotherapy for retinoblastoma: real-world comparison between primary and secondary treatments Retina, 39 (12) (2019), pp. 2264-2272, 10.1097/IAE.0000000000002315

71 N. Grigorovski, E. Lucena, C. Mattosinho, et al.Use of intra-arterial chemotherapy for retinoblastoma: results of a survey Int J Ophthalmol, 7 (4) (2014), pp. 726-730, 10.3980/j.issn.2222-3959.2014.04.26

72 F.L. Munier, M.-C. Gaillard, A. Balmer, et al.Intravitreal chemotherapy for vitreous seeding in retinoblastoma: recent advances and perspectives Saudi J Ophthalmol, 27 (3) (2013), pp. 147-150, 10.1016/j.sjopt.2013.06.003

73 N. Bornfeld, E. Biewald, S. Bauer, et al.The interdisciplinary diagnosis and treatment of intraocular tumors Dtsch Arztebl Int, 115 (7) (2018), pp. 106-111, 10.3238/arztebl.2018.0106

74 D.H. Abramson, R.M. Ellsworth, G.W. RozakisCryotherapy for retinoblastoma Arch Ophthalmol, 100 (8) (1982), pp. 1253-1256, 10.1001/archopht.1982.01030040231003

75 H.S.L. Chan, B.L. Gallie, F.L. Munier, et al.Chemotherapy for retinoblastoma Ophthalmol Clin North Am, 18 (1) (2005), pp. 55-63, 10.1016/j.ohc.2004.11.002

76 B.L. Gallie, A. Budning, G. DeBoer, et al.Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy Arch Ophthalmol, 114 (11) (1996), pp. 1321-1328, 10.1001/archopht.1996.01100140521001

77 S.U. Shah, C.L. Shields, C.G. Bianciotto, et al.Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma Ophthalmology, 121 (1) (2014), pp. 269-275, 10.1016/j.ophtha.2013.08.039

78 H. Augustine, M. Munro, F. Adatia, et al.Treatment of ocular metastasis with anti-VEGF: a literature review and case report Can J Ophthalmol, 49 (5) (2014), pp. 458-463, 10.1016/j.jcjo.2014.06.008

79 G.B. Jaissle, A. Ulmer, S. Henke-Fahle, et al.Suppression of melanoma-associated neoangiogenesis by bevacizumab Arch Dermatol, 144 (4) (2008), pp. 525-527, 10.1001/archdermatol.2007.38

80 X. Chen, Q. Wu, P. Depeille, et al.RasGRP3 mediates MAPK pathway activation in GNAQ mutant uveal melanoma Cancer Cell, 31 (5) (2017), pp. 685-696, 10.1016/j.ccell.2017.04.002

81 R.D. Carvajal, J.A. Sosman, J.F. Quevedo, et al.Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial JAMA, 311 (23) (2014), pp. 2397-2405, 10.1001/jama.2014.6096

82 S. Piperno-Neumann, J. Larkin, R.D. Carvajal, et al.Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071 Mol Cancer Therapeut, 19 (4) (2020), pp. 1031-1039, 10.1158/1535-7163.MCT-19-0098

83 E.S. Rantala, M. HernbergKivelä TtJMr. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis Melanoma Res, 29 (6) (2019), p. 561, 10.1097/CMR.0000000000000575

84 K.N. Smit, M.J. Jager, A. de Klein, et al.Uveal melanoma: towards a molecular understanding Prog Retin Eye Res, 75 (2020), p. 100800, 10.1016/j.preteyeres.2019.100800

85 P. Nathan, J.C. Hassel, P. Rutkowski, et al.Overall survival benefit with tebentafusp in metastatic uveal melanoma N Engl J Med, 385 (13) (2021), pp. 1196-1206, 10.1056/NEJMoa2103485

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Understanding parental hurdles in accessing strabismus treatment

Global research trends in the treatment of squamous cell carcinoma over the past decade: A bibliometric analysis

Global incidence and prevalence in uveal melanoma

A UV-related risk analysis in ophthalmic malignancies: Increased UV exposure may cause ocular malignancies

Genomic instability and eye diseases

Related Author

Barun Kumar

Pooja Kumari

Mittali Khurana

Srishti Sharma

Sanjeev Kumar Mittal

Himani Pal

Anupam Singh

Omna Chawla

Related Institution

Department of Cardiology, AIIMS Rishikesh, Uttarakhand

Department of Ophthalmology, AIIMS Rishikesh, Uttarakhand

Department of Physiology, Government Doon Medical College, Dehradun, Uttarakhand

Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine

Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases

⁰